179 related articles for article (PubMed ID: 37395989)
21. Reviewing the Demographic, Prognostic, and Treatment Factors of Primary Adenocarcinoma of the Bladder: A SEER Population-based Study.
Natale C; Leinwand GZ; Chiang J; Silberstein JL; Krane LS
Clin Genitourin Cancer; 2019 Oct; 17(5):380-388. PubMed ID: 31395362
[TBL] [Abstract][Full Text] [Related]
22. Is Surgical Resection of the Primary Site Associated with an Improved Overall Survival for Patients with Primary Malignant Bone Tumors Who Have Metastatic Disease at Presentation?
Malik AT; Alexander JH; Mayerson JL; Khan SN; Scharschmidt TJ
Clin Orthop Relat Res; 2020 Oct; 478(10):2284-2295. PubMed ID: 32667758
[TBL] [Abstract][Full Text] [Related]
23. Laryngeal adenocarcinoma not otherwise specified: A population-based perspective.
Spinazzi EF; Abboud MT; Dubal PM; Verma SP; Park RC; Baredes S; Eloy JA
Laryngoscope; 2017 Feb; 127(2):424-429. PubMed ID: 27140822
[TBL] [Abstract][Full Text] [Related]
24. Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary.
Bochtler T; Reiling A; Endris V; Hielscher T; Volckmar AL; Neumann O; Kirchner M; Budczies J; Heukamp LC; Leichsenring J; Allgäuer M; Kazdal D; Löffler H; Weichert W; Schirmacher P; Stenzinger A; Krämer A
Int J Cancer; 2020 Jun; 146(11):3053-3064. PubMed ID: 31970771
[TBL] [Abstract][Full Text] [Related]
25. Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature.
Overby A; Duval L; Ladekarl M; Laursen BE; Donskov F
Clin Genitourin Cancer; 2019 Feb; 17(1):e32-e37. PubMed ID: 30268423
[TBL] [Abstract][Full Text] [Related]
26. Comparison of survival of patients with metastases from known versus unknown primaries: survival in metastatic cancer.
Riihimäki M; Thomsen H; Hemminki A; Sundquist K; Hemminki K
BMC Cancer; 2013 Jan; 13():36. PubMed ID: 23356713
[TBL] [Abstract][Full Text] [Related]
27. Carcinoma of unknown primary: retrospective study of 437 patients treated at Salah Azaiez Institute.
Fehri R; Rifi H; Alboueiri A; Malouche D; Ayadi M; Rais H; Mezlini A
Tunis Med; 2013 Mar; 91(3):205-8. PubMed ID: 23588636
[TBL] [Abstract][Full Text] [Related]
28. Carcinomas of an unknown primary origin--diagnosis and treatment.
Massard C; Loriot Y; Fizazi K
Nat Rev Clin Oncol; 2011 Nov; 8(12):701-10. PubMed ID: 22048624
[TBL] [Abstract][Full Text] [Related]
29. Clinical presentation of carcinoma of unknown primary: 14 years of experience.
Yi JH; La Choi Y; Lee SJ; Ahn HK; Baek KK; Lim T; Lee DJ; Han BR; Lee HY; Jun HJ; Lee J; Park YH
Tumour Biol; 2011 Feb; 32(1):45-51. PubMed ID: 20697986
[TBL] [Abstract][Full Text] [Related]
30. Hepatic metastases from carcinomas of unknown primary site.
Pouessel D; Thezenas S; Culine S; Becht C; Senesse P; Ychou M
Gastroenterol Clin Biol; 2005 Dec; 29(12):1224-32. PubMed ID: 16518276
[TBL] [Abstract][Full Text] [Related]
31. Comparison of outcomes between rectal squamous cell carcinoma and adenocarcinoma.
Chiu MS; Verma V; Bennion NR; Bhirud AR; Li J; Charlton ME; Are C; Lin C
Cancer Med; 2016 Dec; 5(12):3394-3402. PubMed ID: 27781400
[TBL] [Abstract][Full Text] [Related]
32. Neuroendocrine carcinoma of unknown primary: a systematic review of the literature and a comparative study with other neuroendocrine tumors.
Stoyianni A; Pentheroudakis G; Pavlidis N
Cancer Treat Rev; 2011 Aug; 37(5):358-65. PubMed ID: 21481536
[TBL] [Abstract][Full Text] [Related]
33. Sarcomatoid carcinoma presenting as cancers of unknown primary: a clinicopathological portrait.
Huey RW; Makawita S; Xiao L; Matamoros A; Estrella JS; Overman MJ; Varadhachary GR; Raghav K
BMC Cancer; 2019 Oct; 19(1):965. PubMed ID: 31623602
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological characteristics and survival outcomes in neuroendocrine prostate cancer: A population-based study.
Zhu J; Liang X; Wu D; Chen S; Yang B; Mao W; Shen D
Medicine (Baltimore); 2021 Apr; 100(15):e25237. PubMed ID: 33847621
[TBL] [Abstract][Full Text] [Related]
35. Treatment and Survival of Small-bowel Adenocarcinoma in the United States: A Comparison With Colon Cancer.
Young JI; Mongoue-Tchokote S; Wieghard N; Mori M; Vaccaro GM; Sheppard BC; Tsikitis VL
Dis Colon Rectum; 2016 Apr; 59(4):306-15. PubMed ID: 26953989
[TBL] [Abstract][Full Text] [Related]
36. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma?
Lenzi R; Hess KR; Abbruzzese MC; Raber MN; Ordoñez NG; Abbruzzese JL
J Clin Oncol; 1997 May; 15(5):2056-66. PubMed ID: 9164218
[TBL] [Abstract][Full Text] [Related]
37. Carcinoma NOS is a common histologic diagnosis and is increasing in proportion among non-small cell lung cancer histologies.
Ou SH; Zell JA
J Thorac Oncol; 2009 Oct; 4(10):1202-11. PubMed ID: 19701111
[TBL] [Abstract][Full Text] [Related]
38. Impact of cytoreductive surgery on outcomes of metastatic appendiceal carcinoma: a real-world, population-based study.
Abdel-Rahman O
J Comp Eff Res; 2020 Apr; 9(6):431-439. PubMed ID: 32253936
[No Abstract] [Full Text] [Related]
39. Surgery to the primary tumor is associated with improved survival of patients with metastatic esophageal cancer: propensity score-matched analyses of a large retrospective cohort.
Zhang R; Zou J; Li P; Li Q; Qiao Y; Han J; Huang K; Ruan P; Lin H; Song Q; Fu Z
Dis Esophagus; 2020 Mar; 33(3):. PubMed ID: 31175353
[TBL] [Abstract][Full Text] [Related]
40. Diagnosis and management of metastatic neoplasms with unknown primary.
Bochtler T; Löffler H; Krämer A
Semin Diagn Pathol; 2018 May; 35(3):199-206. PubMed ID: 29203116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
